These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9734243)

  • 1. Smart estrogens may decrease heart-attack risk.
    Harv Heart Lett; 1998 Sep; 9(1):2. PubMed ID: 9734243
    [No Abstract]   [Full Text] [Related]  

  • 2. 'Smart' estrogens emerging.
    Harv Heart Lett; 1998 Mar; 8(7):4-5. PubMed ID: 9516317
    [No Abstract]   [Full Text] [Related]  

  • 3. Raloxifene: a selective estrogen receptor modulator.
    Scott JA; Da Camara CC; Early JE
    Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does raloxifene reduce breast cancer risk?
    Mattimoe D; Newton W
    J Fam Pract; 1999 Sep; 48(9):659-60. PubMed ID: 10498063
    [No Abstract]   [Full Text] [Related]  

  • 5. HRT and SERMS--increasing benefit, reducing risk?
    Jackson G
    Int J Clin Pract; 1998; 52(1):3. PubMed ID: 9536557
    [No Abstract]   [Full Text] [Related]  

  • 6. [Raloxifene: a new molecule for the prevention of menopausal osteoporosis].
    Oliaro A
    Minerva Ginecol; 1998 Mar; 50(3):XII-XIII. PubMed ID: 9595915
    [No Abstract]   [Full Text] [Related]  

  • 7. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
    Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ
    Menopause; 1999; 6(3):188-95. PubMed ID: 10486787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Raloxifene].
    Hofbauer LC; Heufelder AE
    Dtsch Med Wochenschr; 1999 Jan; 124(1-2):19-20. PubMed ID: 9951454
    [No Abstract]   [Full Text] [Related]  

  • 9. Raloxifene: designer estrogen for preventing postmenopausal osteoporosis.
    Park L; Evans MF
    Can Fam Physician; 1999 May; 45():1191-3. PubMed ID: 10349062
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current trends in prevention and therapy of postmenopausal osteoporosis].
    Rossi G
    Recenti Prog Med; 1998 Jun; 89(6):288. PubMed ID: 9658894
    [No Abstract]   [Full Text] [Related]  

  • 11. Raloxifene: a new class of anti-estrogens for the prevention of osteoporosis.
    Kupecz D
    Nurse Pract; 1998 Sep; 23(9):91-3. PubMed ID: 9778672
    [No Abstract]   [Full Text] [Related]  

  • 12. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
    Mijatovic V; van der Mooren MJ; Kenemans P; de Valk-de Roo GW; Netelenbos C
    Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Of designer drugs, magic bullets, and gold standards.
    Rifkind BM; Rossouw JE
    JAMA; 1998 May; 279(18):1483-5. PubMed ID: 9600485
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of raloxifene in postmenopausal women.
    Friedman MN
    N Engl J Med; 1998 Apr; 338(18):1313; author reply 1313-4. PubMed ID: 9565493
    [No Abstract]   [Full Text] [Related]  

  • 15. Designer estrogens: breast cancer benefit, remaining questions.
    Health News; 1999 Jul; 5(9):6. PubMed ID: 10480007
    [No Abstract]   [Full Text] [Related]  

  • 16. [Estrogen agonists, especially raloxifene, in the treatment of osteoporosis].
    Lips P; Netelenbos JC
    Ned Tijdschr Geneeskd; 1996 Jun; 140(23):1215-7. PubMed ID: 8700270
    [No Abstract]   [Full Text] [Related]  

  • 17. New estrogen may hold greater appeal.
    Harv Health Lett; 1998 Mar; 23(5):7. PubMed ID: 9536666
    [No Abstract]   [Full Text] [Related]  

  • 18. I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a day to stave off osteoporosis. What's left?
    Robb-Nicholson C
    Harv Womens Health Watch; 1998 Nov; 6(3):8. PubMed ID: 9814138
    [No Abstract]   [Full Text] [Related]  

  • 19. New drug approved to help prevent osteoporosis.
    Mayo Clin Health Lett; 1998 Mar; 16(3):3. PubMed ID: 9516369
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
    Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.